Summary. It is not practical to quantitate gonadotropin in the blood of normal men and women by utilizing bioassays. We have developed a method for sensitive, precise, and specific radioimmunoassay of luteinizing hormone (LH) in human serum or plasma. Antisera were developed against human chorionic gonadotropin, and one of these was selected for extensive cross-reaction with human LH. Highly purified LH was radioiodinated by the method of Greenwood, Hunter, and Glover. Separation of antibody-bound from free LH-131I was accomplished by a double antibody technique. Dose-response curves for the purified LH, an impure urinary LH preparation, pituitary powder, and LH in plasma were all identical. Immunoassay and bioassay of impure urinary and pituitary gonadotropin preparations in terms of a common standard resulted in an index of discrimination of close to unity. LH levels in plasma from 32 adult men and 30 women outside the midcycle ranged from 0.6 to 3.2 mfAg per ml (1 m/Ag of our laboratory LH standard is equivalent to 8 mU of the Second International Reference Preparation of Human Menopausal Gonadotropin). Levels were remarkably constant in men from day to day and in women except at midcycle, when a sharp peak occurred lasting less than 24 hours. In all women studied who had a midcycle LH peak, mean plasma LH levels during the follicular phase of the menstrual cycle were higher than mean values obtained during the luteal phase. Prepubertal children had detectable plasma LH, and mean values were only slightly less than in adults. Plasma from castrate men or women or postmenopausal women contained 4.5 to 10.5 mug per ml. Clomiphene treatment of four men resulted in a doubling of plasma LH in 5 days. Introduction Wide, Roos, and Gemzell (1), using an immunoassay based on hemagglutination inhibition, first reported that human luteinizing hormone (HLH) cross-reacts with human chorionic gonadotropin (HCG) for binding to antibodies directed against HCG. In 1964 Paul and Odell (2) first developed a radioimmunoassay for HCG.
Introduction
Wide, Roos, and Gemzell (1), using an immunoassay based on hemagglutination inhibition, first reported that human luteinizing hormone (HLH) cross-reacts with human chorionic gonadotropin (HCG) for binding to antibodies directed against HCG. In 1964 Paul and Odell (2) first developed a radioimmunoassay for HCG.
Later we (3) developed a radioimmunoassay for HLH by taking advantage of the cross-reaction between HLH and HCG and the availability of a highly purified preparation of HLH suitable for radioiodination.
In 1965 Midgley and Ram (4) published an abstract of methods of radioimmunoassay for HLH, and subsequently Midgley (5) and Franchimont (6) published reports of methods for radioimmunoassay for HLH. We wish to report details of our methodology and some results of physiological studies.
Methods
Preparation of antisera to HLH (anti-HLH). All immunizations were performed by dissolving the antigen 248 in saline and emulsifying this solution with an equal volume of complete Freund's adjuvant.' Three ml of this mixture was given subcutaneously in two sites to each white New Zealand rabbit. Three such injections were administered 10 days apart. Animals were bled periodically by cardiac puncture starting 10 days after the last injection. Two gonadotropin preparations were used to prepare the antisera: 1) a preparation from urine of pregnant women 2 (3,000 IU was administered in each injection; antisera from 12 animals were studied), and 2) a preparation from urine of castrate men3 (12.5 mg was administered at each injection, and antisera from six animals were studied). All antisera were screened for titer and ability to bind a tracer amount of human luteinizing hormone labeled with "31I (LH-131I) by incubating tenfold dilutions of the antisera with 0.05 mug of LH-'31I. Antisera that bound more than 70% of this antigen at greater than 1:10,000 final dilution were further screened by running abbreviated dose-response curves of unlabeled HLH in the radioimmunoassay system. An antiserum directed against HCG was finally selected to develop the assay described.
Sheep antirabbit antisera were prepared by dissolving 100 mg of rabbit y-globulin4 in 5 ml of 0.9%o NaCl and mixing with 5 ml of complete Freund's adjuvant. Ten ml of this mixture was injected subcutaneously into a sheep on the same schedule as described for rabbits. Two sheep were immunized and periodic bleeding was performed starting 10 days after the last injection. Every batch of antiserum was titered for ability to precipitate the antibody-bound HLH-uI mixture described later. An "excess" (usually 150 ul) was used as the second antibody for assay purposes.
Radioiodinated human luteinizing hormone. One mg of highly purified HLH was utilized in the development of this assay. This particular batch of HLH had not been bioassayed because insufficient material was available, but with similar methodology HLH preparations containing 6,400 IU per mg 5 had been previously prepared (7) . The HLH was dissolved in phosphate saline buffer (0.01 M phosphate, 0.15 M NaCl, pH 7.8) in concentrations of 0.1 mg per ml and frozen in aliquots of 0.2 ml for each assay. One or 2 ,ug of this material was radioiodinated to specific activities of 200 to 500 MAc per lug by the method of Greenwood, Hunter, and Glover (8) . LH-13"I was separated from inorganic 131I by passing through a G75 Sephadex column (1.0 X 15 cm). The trailing edge of the earliest peak was used in the assay. LH-'I was always utilized within 24 to 48 hours of preparation.
Performance of assay. The following buffer was used for all dilutions: 0.01 M phosphate, 0.15 M NaCl, 0.1% 1 Difco Laboratories, Detroit, Mich.
2APL, Ayerst, New York, N. Y. 3 HPGUE, National Institutes of Health study section. 4 Hyland Laboratories, Los Angeles, Calif. 5 In terms of the Second International Reference Preparation of Human Menopausal Gonadotropin (2nd IRP HMG). sodium azide, 2.5% normal rabbit serum, pH 7.8. All reagents were added to 1.0-X 7.5-cm tubes in the following order: 1) buffer to make a total volume of 1.0 ml, 2) 100 Al of 0.1 M EDTA, pH 7.6, 3) 1.0 to 300 ,l of plasma to be assayed (or of "standard" hormone), 4) 100 Ml containing 0.05 to 0.15 mug of HLH-13I, and 5) 100 Ml of antisera suitably diluted, usually 1: 30,000 (final dilution, 1: 300,000).
Complete standard dose-response curves were run in all assays, and for this purpose known amounts of HLH were added instead of the plasma. All tubes were incubated for 5 days at 4°C, at which time 150 Ml of the second antibody was added to each tube and the mixture incubated 24 hours longer at 4°C to achieve separation of antibody-bound from free HLH-'I, according to the method of Feinberg (9) as modified by Morgan, Sorenson, and Lazarow (10) . Tubes were then centrifuged at 500 g and the supernatant was removed by suction. Radioactivity was quantitated in an automatic gamma spectrometer, 6 and all results were expressed as per cent of counts precipitated. Zero per cent was defined as no HLH-'I bound to antibody. Two to 5% of HLH-'I was trapped in the precipitate nonspecifically, the value of these counts being obtained by quantitating precipitated counts in tubes containing no antibody. These counts could be removed by washing the precipitate, but this did not contribute significantly to precision of the assay, and this step was therefore omitted. The counter was then set so that these counts were automatically subtracted (as background). One hundred per cent was defined as the number of counts precipitated in tubes containing HLH-'31I and antibody, but no unknown or standard LH. All tubes were counted for the time required for the "100%o tubes" to register 10,000 counts. Thus any tubes with unlabeled HLH present had HLH-'31I "displaced" from antibody, and the result was less than 10,000 counts precipitated. In this manner all results were expressed in relation to 10,000 counts and by shifting the decimal two places to the left were expressed as per cent. This procedure greatly simplified data processing.
Bioassay. Several samples were simultaneously bioassayed and immunoassayed in terms of the same human standard. Bioassays for HLH were done by means of the ventral prostate weight in hypophysectomized immature male rats (11) . It is important to note that a human LH standard is required for the purposes of radioimmunoassay because LH of other species reacts poorly or not at all in the assay. Pergonal 1958 7 was adopted as our laboratory standard for both bioassays and immunoassays. After repeated potency estimates in the radioimmunoassay 1 Mg of this laboratory standard was defined as equivalent to 2 m/g of purified HLH and as equivalent to 0.016 IU 8 of LH. 6 Picker X-Ray Corp., White Plains, N. Y. 7 Purchased from Instituto Farmacologico, Serono, Rome, Italy. 8 In terms of international units of the 2nd IRP HMG.
Results Ninety-five per cent or more of the HLH-131I was precipitable in the presence of excess anti-HLH. Figure 1 demonstrates a semilogarithmic dose-response curve for the purified HLH in the radioimmunoassay. The minimal amount detectable was 0.15 mJxg per ml (1.2 mU) of plasma when 300 pd was assayed in each milliliter of reaction mixture. Also shown in Figure 1 tions from a number of sources have been assayed by this technique to assist in evaluation of specificity. Highly purified HFSH, which initially assayed biologically at 100 IU per mg,9 gave a dose-response curve identical to that of the HLH except that 100 times as much material (by weight) was required to give the same response, a phenomenon probably explained by a 1 % contamination of the HFSH with HLH. Human thyrotropin (HTSH), which initially assayed at 20 U per mg, also gave a dose-response curve identical to the HLH, but 20 times as much was required for the same response, a phenomenon probably explained by 5% contamination of the HTSH with HLH. The values for per cent contamination are similar to those obtained for both HTSH (12) and HFSH (13) by bioassay. The dose-response curve for human chorionic gonadotropin is also identical to HLH. As little as 0.002 IU 10 may be detected. This is 50 times more sensitive than the mouse uterine weight assay (14) . It is interesting that monkey chorionic gonadotropin shows minimal cross-reaction in this assay for HLH, as much as 100 IU giving the same response as 0.01 IU of HCG. The differences in monkey and human chorionic gonadotropin will be presented in detail in a separate publication. 9 Obtained through the kind generosity of Dr. Leo Reichert, Dept. of Biochemistry, Emory University, Atlanta, Ga. 10 The international unit of HCG is different from the international unit of the 2nd IRP HMG. Several impure gonadotropin preparations (containing both LH and FSH) were simultaneously assayed in the radioimmunoassay and in the prostate weight assay in terms of a common standard. Results are presented in Table I . For several samples only enough LH was present to permit a 1 on 2 bioassay design. The index of discrimination was close to unity in all cases, and in all cases the 95%o confidence limits of the potency estimate by bioassay included the potency estimate by immunoassay.
Plasma from a number of sources has been examined for HLH content, and a scattergram of some of these data is presented in Figure 3 . Plasma from eugonadal men and women except at midcycle contained an average of 1.8 mjug per ml (range from 0.8 to 3.2). In men plasma values for HLH appeared fairly constant. Samples from four men under normal activity were obtained every 6 hours for 4 days and for two of these same men at times when 24-hour bed rest was maintained. No diurnal variation of HLH has been observed under any of these conditions. Plasma from children of both sexes between the ages of 8 and 12 years contained an average of 1.6 mug per ml (0.6 to 2), and plasma from children 1 to 8 years of age contained an average of 1.0 m/Ag per ml (0.6 to 1.6). The differences among all four of these groups are not statistically significant. The presence of gonadotropin in plasma from prepubertal children is discussed in more detail later.
Plasma fairly constant except at midcycle, where a sharp peak occurred. The mean plasma level of LH was higher during the follicular phase than during the luteal phase. Also shown are basal body temperatures and pregnanediol excretion. We have followed such changes through a menstrual cycle in 30 women, and the midcycle peak was typically seen at the suspected time of ovulation in 27. In three women anovulatory cycles were suspected because of a delay of 10 to 20 days in arrival of expected menses, and no midcycle peak was observed. Figure 5 depicts the LH values obtained during the luteal phase were less than those obtained during the follicular phase. Treatment of 11 of these women with an oral contraceptive agent (Enovid E, 2.5 mg per day) for the next consecutive cycle after the one reported resulted in a complete suppression of this LH peak. (26) .
The presence of gonadotropins in urine and plasma prepubertally suggests that a dynamic pituitary-gonadal interreaction may exist before puberty in man. Such a relationship has been demonstrated in animals. Plasma from prepubertal rats contains LH that is detectable by its effects on a parabiont hypophysectomized partner (27) . When immature rats are joined in parabiosis and one partner is castrated, the other undergoes precocious sexual development (28) . This sexual development may be prevented by treatment of the castrate animal with estrogenic steroids in doses that are too small to have any effect on the sex accessories (29) . A number of studies are in progress in our laboratory to further elucidate mechanisms of puberty. We have recently observed two prepubertal girls, one age 11, one age 12, with castrate levels of plasma LH; both girls have been found to have no gonadal tissue.
The facts that LH is detectable in blood of prepubertal children and that the levels are only slightly lower than in adults challenge our present concepts of mechanisms of puberty. It appears that puberty is not simply caused by onset of gonadotropin secretion, which in turn stimulates gonadal steroid secretion, but by a more complex phenomenon that involves a dynamic pituitarygonadal interrelation before sexual maturation.
The preliminary observations on elevations of plasma LH in response to clomiphene treatment indicated that this may be usable as a test of pituitary LH "reserve" in a fashion similar to the insulin hypoglycemia (20) or pyrogen-induced (21) elevation of growth hormone or to the metopirone release of ACTH (22) .
